Tags

Type your tag names separated by a space and hit enter

Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010.
Braz J Infect Dis. 2013 Sep-Oct; 17(5):564-72.BJ

Abstract

Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a cephalosporin with in vitro bactericidal activity against Gram-positive organisms, including methicillin-susceptible and -resistant Staphylococcus aureus, β-haemolytic and viridans group streptococci, and Streptococcus pneumoniae, as well as common Gram-negative organisms. In this study a total of 986 isolates collected in 2010 from patients in 15 medical centers in five Latin American countries from the Assessing Worldwide Antimicrobial Resistance Evaluation Program were identified as community-acquired respiratory tract or skin and soft tissue infection pathogens. Ceftaroline was the most potent agent tested against S. pneumoniae with a MIC90 value (0.12μg/mL) that was eight-fold lower than ceftriaxone, levofloxacin, and linezolid. Its spectrum of coverage (100.0% susceptible) was similar to tigecycline, linezolid, levofloxacin and vancomycin. Against Haemophilus influenzae and Moraxella catarrhalis, ceftaroline was the most active agent tested. The activity of ceftaroline against S. aureus (including MRSA) was similar to that of vancomycin and tetracycline (MIC90, 1μg/mL) and linezolid (MIC90, 2μg/mL). The β-haemolytic streptococci exhibited 100.0% susceptibility to ceftaroline. Ceftaroline activity against Escherichia coli, Klebsiella spp., and Enterobacter spp. was similar to that of ceftriaxone and ceftazidime. These parenteral cephalosporin agents have potent activity against non-extended-spectrum β-lactamase-phenotype strains, but are not active against extended-spectrum β-lactamase-phenotype strains. These results confirm the in vitro activity of ceftaroline against pathogens common in community-acquired respiratory tract and skin and soft tissue infection in Latin America, and suggest that ceftaroline fosamil could be an important therapeutic option for these infections.

Authors+Show Affiliations

JMI Laboratories, North Liberty, IA, USA. Electronic address: robert-flamm@jmilabs.com.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23916453

Citation

Flamm, Robert K., et al. "Spectrum and Potency of Ceftaroline Against Leading Pathogens Causing Community-acquired Respiratory Tract and Skin and Soft Tissue Infections in Latin America, 2010." The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases, vol. 17, no. 5, 2013, pp. 564-72.
Flamm RK, Sader HS, Jones RN. Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010. Braz J Infect Dis. 2013;17(5):564-72.
Flamm, R. K., Sader, H. S., & Jones, R. N. (2013). Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010. The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases, 17(5), 564-72. https://doi.org/10.1016/j.bjid.2013.02.008
Flamm RK, Sader HS, Jones RN. Spectrum and Potency of Ceftaroline Against Leading Pathogens Causing Community-acquired Respiratory Tract and Skin and Soft Tissue Infections in Latin America, 2010. Braz J Infect Dis. 2013 Sep-Oct;17(5):564-72. PubMed PMID: 23916453.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010. AU - Flamm,Robert K, AU - Sader,Helio S, AU - Jones,Ronald N, Y1 - 2013/07/31/ PY - 2013/01/07/received PY - 2013/02/15/accepted PY - 2013/8/7/entrez PY - 2013/8/7/pubmed PY - 2014/1/28/medline KW - AWARE KW - Ceftaroline KW - S. aureus KW - S. pneumoniae SP - 564 EP - 72 JF - The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases JO - Braz J Infect Dis VL - 17 IS - 5 N2 - Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a cephalosporin with in vitro bactericidal activity against Gram-positive organisms, including methicillin-susceptible and -resistant Staphylococcus aureus, β-haemolytic and viridans group streptococci, and Streptococcus pneumoniae, as well as common Gram-negative organisms. In this study a total of 986 isolates collected in 2010 from patients in 15 medical centers in five Latin American countries from the Assessing Worldwide Antimicrobial Resistance Evaluation Program were identified as community-acquired respiratory tract or skin and soft tissue infection pathogens. Ceftaroline was the most potent agent tested against S. pneumoniae with a MIC90 value (0.12μg/mL) that was eight-fold lower than ceftriaxone, levofloxacin, and linezolid. Its spectrum of coverage (100.0% susceptible) was similar to tigecycline, linezolid, levofloxacin and vancomycin. Against Haemophilus influenzae and Moraxella catarrhalis, ceftaroline was the most active agent tested. The activity of ceftaroline against S. aureus (including MRSA) was similar to that of vancomycin and tetracycline (MIC90, 1μg/mL) and linezolid (MIC90, 2μg/mL). The β-haemolytic streptococci exhibited 100.0% susceptibility to ceftaroline. Ceftaroline activity against Escherichia coli, Klebsiella spp., and Enterobacter spp. was similar to that of ceftriaxone and ceftazidime. These parenteral cephalosporin agents have potent activity against non-extended-spectrum β-lactamase-phenotype strains, but are not active against extended-spectrum β-lactamase-phenotype strains. These results confirm the in vitro activity of ceftaroline against pathogens common in community-acquired respiratory tract and skin and soft tissue infection in Latin America, and suggest that ceftaroline fosamil could be an important therapeutic option for these infections. SN - 1678-4391 UR - https://www.unboundmedicine.com/medline/citation/23916453/Spectrum_and_potency_of_ceftaroline_against_leading_pathogens_causing_community_acquired_respiratory_tract_and_skin_and_soft_tissue_infections_in_Latin_America_2010_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1413-8670(13)00161-X DB - PRIME DP - Unbound Medicine ER -